The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation

  • Ock, Chan-Young (Department of Internal Medicine, Seoul National University Hospital) ;
  • Keam, Bhumsuk (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Tae Min (Department of Internal Medicine, Seoul National University Hospital) ;
  • Han, Doo Hee (Department of Otorhinolaryngology, Seoul National University Hospital) ;
  • Won, Tae-Bin (Department of Otorhinolaryngology, Seoul National University Hospital) ;
  • Lee, Se-Hoon (Department of Internal Medicine, Seoul National University Hospital) ;
  • Hah, J. Hun (Department of Otorhinolaryngology, Seoul National University Hospital) ;
  • Kwon, Tack-Kyun (Department of Otorhinolaryngology, Seoul National University Hospital) ;
  • Kim, Dong-Wan (Department of Internal Medicine, Seoul National University Hospital) ;
  • Kim, Dong-Young (Department of Otorhinolaryngology, Seoul National University Hospital) ;
  • Rhee, Chae-Seo (Department of Otorhinolaryngology, Seoul National University Hospital) ;
  • Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Sung, Myung-Whun (Department of Otorhinolaryngology, Seoul National University Hospital) ;
  • Heo, Dae Seog (Department of Internal Medicine, Seoul National University Hospital)
  • Received : 2015.01.28
  • Accepted : 2015.05.12
  • Published : 2016.05.01
⟨ Previous Next ⟩

Abstract

Background/Aims: The role of induction chemotherapy (IC) for eyeball preservation has not been established in head and neck squamous cell carcinoma (HNSCC) of the paranasal sinus and nasal cavity (PNSNC). Periorbital involvement frequently leads to eyeball exenteration with a margin of safety. We evaluated the treatment outcomes, including survival and eyeball preservation, of patients who received IC for HNSCC of the PNSNC. Methods: We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC. We analyzed response, eyeball preservation rate, and overall survival. Results: Tumors were located in the paranasal sinus (n = 14) or nasal cavity (n = 7). Most patients had stage T4a (n = 10) or T4b (n = 7) disease. More than half of the patients received a chemotherapy regimen of docetaxel, fluorouracil, and cisplatin (n = 11). Thirteen patients (61.9%) achieved a partial response after IC and 15 patients (71.4%) achieved T down-staging. Among 17 patients with stage T4 disease, which confers a high risk of orbital exenteration, 14 (82.4%) achieved preservation of the involved eye. The 3-year overall survival (OS) rate of patients who achieved a partial response to IC was 84.6%. The 3-year OS rate of patients with stable disease or disease progression after IC was 25.0% (p = 0.038). Conclusions: IC could be considered for down-staging patients with advanced T-stage disease. It could also be a reasonable option for eyeball preservation in locally advanced HNSCC of the PNSNC.

Keywords

Acknowledgement

Supported by : Seoul National University Hospital

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29. https://doi.org/10.3322/caac.20138
  2. Batsakis JG. Tumours of the Head and Neck: Clinical and Pathological Considerations. 2nd ed. Baltimore: Lippincott Williams and Wilkins, 1979.
  3. Pignon JP, le Maitre A, Maillard E, Bourhis J; MACHNC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14. https://doi.org/10.1016/j.radonc.2009.04.014
  4. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-1154. https://doi.org/10.1056/NEJMra0707975
  5. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098. https://doi.org/10.1056/NEJMoa031317
  6. Tobias JS, Monson K, Gupta N, et al. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol 2010;11:66-74. https://doi.org/10.1016/S1470-2045(09)70306-7
  7. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 2001;92:3012-3029. https://doi.org/10.1002/1097-0142(20011215)92:12<3012::AID-CNCR10131>3.0.CO;2-E
  8. Ganly I, Patel SG, Singh B, et al. Craniofacial resection for malignant paranasal sinus tumors: report of an international collaborative study. Head Neck 2005;27:575-584. https://doi.org/10.1002/hed.20165
  9. Guntinas-Lichius O, Kreppel MP, Stuetzer H, Semrau R, Eckel HE, Mueller RP. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol 2007;33:222-228. https://doi.org/10.1016/j.ejso.2006.10.033
  10. Snyers A, Janssens GO, Twickler MB, et al. Malignant tumors of the nasal cavity and paranasal sinuses: longterm outcome and morbidity with emphasis on hypothalamic-pituitary deficiency. Int J Radiat Oncol Biol Phys 2009;73:1343-1351. https://doi.org/10.1016/j.ijrobp.2008.07.040
  11. Ahmad K, Cordoba RB, Fayos JV. Squamous cell carcinoma of the maxillary sinus. Arch Otolaryngol 1981;107:48-51. https://doi.org/10.1001/archotol.1981.00790370050011
  12. Marchetta FC, Sako K, Mattick WL, Stinziano GD. Squamous cell carcinoma of the maxillary antrum. Am J Surg 1969;118:805-807. https://doi.org/10.1016/0002-9610(69)90234-7
  13. McCary WS, Levine PA, Cantrell RW. Preservation of the eye in the treatment of sinonasal malignant neoplasms with orbital involvement: a confirmation of the original treatise. Arch Otolaryngol Head Neck Surg 1996;122:657-659. https://doi.org/10.1001/archotol.1996.01890180063015
  14. Perry C, Levine PA, Williamson BR, Cantrell RW. Preservation of the eye in paranasal sinus cancer surgery. Arch Otolaryngol Head Neck Surg 1988;114:632-634. https://doi.org/10.1001/archotol.1988.01860180046027
  15. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-1690. https://doi.org/10.1056/NEJM199106133242402
  16. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial: EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890-899. https://doi.org/10.1093/jnci/88.13.890
  17. Lee YY, Dimery IW, Van Tassel P, De Pena C, Blacklock JB, Goepfert H. Superselective intra-arterial chemotherapy of advanced paranasal sinus tumors. Arch Otolaryngol Head Neck Surg 1989;115:503-511. https://doi.org/10.1001/archotol.1989.01860280101026
  18. Rosen A, Vokes EE, Scher N, Haraf D, Weichselbaum RR, Panje WR. Locoregionally advanced paranasal sinus carcinoma: favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg 1993;119:743-746. https://doi.org/10.1001/archotol.1993.01880190039008
  19. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, et al. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer 2003;98:2214-2223. https://doi.org/10.1002/cncr.11771
  20. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-8645. https://doi.org/10.1200/JCO.2004.00.1990
  21. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-1704. https://doi.org/10.1056/NEJMoa071028
  22. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715. https://doi.org/10.1056/NEJMoa070956
  23. Jang NY, Wu HG, Park CI, et al. Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. Jpn J Clin Oncol 2010;40:542-548. https://doi.org/10.1093/jjco/hyq009
  24. Hanna EY, Cardenas AD, DeMonte F, et al. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg 2011;137:78-81. https://doi.org/10.1001/archoto.2010.231
  25. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. https://doi.org/10.1016/j.ejca.2008.10.026
  26. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010.
  27. Cohen EE, Karrison T, Kocherginsky M, et al. DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2012;30(15 Suppl):5500.
  28. Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013;14:257-264. https://doi.org/10.1016/S1470-2045(13)70011-1
  29. Hitt R, Grau JJ, Lopez-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2014;25:216-225. https://doi.org/10.1093/annonc/mdt461
  30. Ghi MG, Paccagnella A, Ferrari D, et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction docetaxel/cisplatin/5-fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN): a randomized phase III factorial study (NCT01086826). J Clin Oncol 2014;32(15 Suppl):6004.
  31. Rajapurkar M, Thankappan K, Sampathirao LM, Kuriakose MA, Iyer S. Oncologic and functional outcome of the preserved eye in malignant sinonasal tumors. Head Neck 2013;35:1379-1384.
  32. Nishino H, Takanosawa M, Kawada K, et al. Multidisciplinary therapy consisting of minimally invasive resection, irradiation, and intra-arterial infusion of 5-fluorouracil for maxillary sinus carcinomas. Head Neck 2013;35:772-778. https://doi.org/10.1002/hed.23030